Cogent Biosciences Inc
Company Profile
Business description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Contact
275 Wyman Street
3rd Floor
WalthamMA02451
USAT: +1 617 945-5576
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
205
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,475.20 | 12.60 | 0.15% |
| CAC 40 | 7,743.75 | 49.31 | 0.64% |
| DAX 40 | 23,499.32 | 146.63 | 0.63% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,554.80 | 23.19 | 0.27% |
| HKSE | 23,114.31 | 246.57 | 1.08% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,612.90 | 109.57 | 0.29% |
| NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
| S&P 500 | 5,659.91 | 4.03 | -0.07% |
| S&P/ASX 200 | 8,242.80 | 11.60 | 0.14% |
| SSE Composite Index | 3,356.98 | 14.98 | 0.45% |